A review and recommendations for oral chaperone therapy in adult patients with Fabry disease

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
A review and recommendations for oral chaperone therapy in adult patients with Fabry disease ; volume:19 ; number:1 ; day:18 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
Orphanet journal of rare diseases ; 19, Heft 1 (18.1.2024), 1-13, 12.2024

Creator
Nowicki, Michał
Bazan-Socha, Stanisława
Błażejewska-Hyżorek, Beata
Kłopotowski, Mariusz M.
Komar, Monika
Kusztal, Mariusz A.
Liberek, Tomasz
Małyszko, Jolanta
Mizia-Stec, Katarzyna
Oko-Sarnowska, Zofia
Pawlaczyk, Krzysztof
Podolec, Piotr
Sławek, Jarosław
Contributor
SpringerLink (Online service)

DOI
10.1186/s13023-024-03028-w
URN
urn:nbn:de:101:1-2406122112036.161361057749
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:53 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nowicki, Michał
  • Bazan-Socha, Stanisława
  • Błażejewska-Hyżorek, Beata
  • Kłopotowski, Mariusz M.
  • Komar, Monika
  • Kusztal, Mariusz A.
  • Liberek, Tomasz
  • Małyszko, Jolanta
  • Mizia-Stec, Katarzyna
  • Oko-Sarnowska, Zofia
  • Pawlaczyk, Krzysztof
  • Podolec, Piotr
  • Sławek, Jarosław
  • SpringerLink (Online service)

Other Objects (12)

Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease

Correction: A review and recommendations for oral chaperone therapy in adult patients with Fabry disease

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year

Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data”

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World Data”

Hypertension in adult Fabry’s disease: is cardiotrophin-1 a diagnostic biomarker?

Hypertension in adult Fabry’s disease: is cardiotrophin-1 a diagnostic biomarker?

Pain in fabry disease: practical recommendations for diagnosis and treatment

Pain in fabry disease: practical recommendations for diagnosis and treatment

Molekulare Chaperone

Molekulare Chaperone

Co-chaperone interactions in the Hsp90 chaperone cycle

Hochschulschrift

Co-chaperone interactions in the Hsp90 chaperone cycle

Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy

Fabry Nephropathy in a Young Female Patient Presenting with Only Urinary Mulberry Bodies Treated with Chaperone Therapy

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry

COVID-19 Pandemic: Oral Health Challenges and Recommendations

COVID-19 Pandemic: Oral Health Challenges and Recommendations

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

Related objects